Skip to main content

Thomas Joseph Weber

Professor of Medicine
Medicine, Endocrinology, Metabolism, and Nutrition
Duke Box 3470, Durham, NC 27710
303 Baker House, Durham, NC 27710

Overview


Osteoporosis, with current studies that focus on advances in diagnosis and natural history of male and postmenopausal osteoporosis. The study on male osteoporosis include a collaborative study with outside investigators is examining the utility of lateral spine bone densitometry in identifying men with osteoporosis and low trauma fractures.

Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.

Current Appointments & Affiliations


Professor of Medicine · 2021 - Present Medicine, Endocrinology, Metabolism, and Nutrition, Medicine
Member of the Duke Cancer Institute · 2016 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Switching from active vitamin D and phosphate supplementation to burosumab significantly corrects lower limb malalignment in pediatric X-linked hypophosphatemia.

Journal Article J Bone Miner Res · November 29, 2025 X-linked hypophosphatemia (XLH) is a rare disorder of renal phosphate wasting and dysregulated active vitamin D metabolism, ultimately presenting as rickets and osteomalacia, among other manifestations. Lower extremity deformity (genu valgum and/or varum) ... Full text Link to item Cite

Clinical Pearls From JCEM Case Reports: ENDO 2025.

Journal Article JCEM Case Rep · November 2025 Full text Link to item Cite

Pharmacodynamic Exposure-Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH.

Journal Article J Clin Pharmacol · February 2025 X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by excessive fibroblast growth factor 23 (FGF23), leading to low serum phosphate levels resulting in increased risk of fractures and pseudofractures. Burosumab is indicated for the treatment ... Full text Link to item Cite
View All Publications

Recent Grants


Endocrinology and Metabolism Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029

X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP) UX023-CL401

ResearchPrincipal Investigator · Awarded by Ultragenyx Pharmaceutical · 2018 - 2028

Characterizing neurocognitive symptoms in older adults with primary hyperparathyroidism

ResearchCollaborator · Awarded by National Institutes of Health · 2023 - 2025

View All Grants

Education, Training & Certifications


The University of Chicago · 1989 M.D.